Boundless Bio Inc BOLD.O:
BOUNDLESS BIO ANNOUNCES PORTFOLIO PRIORITIZATION AND RUNWAY EXTENSION
BOUNDLESS BIO INC - PRIORITIZES BBI-355/BBI-825 COMBINATION AND BBI-940
BOUNDLESS BIO INC - DISCONTINUES CURRENT ARMS OF BBI-355 IN POTENTIATE TRIAL
BOUNDLESS BIO INC - TO EVALUATE BBI-355/BBI-825 COMBINATION IN 2025
BOUNDLESS BIO INC - REDUCES WORKFORCE BY ONE-THIRD
Source text: ID:nGNX8ZRbgN
Further company coverage: BOLD.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.